Feb. 9 at 3:52 PM
$VKTX added 7.5 mg q 2 wk maintenance dose to its ongoing phase 1-2 study that completed enrollment.
This makes sense , Viking team is getting sound external clinical advice on genuine patient preference.
It is not all about monthly vs wkly
$PFE monthly experience clearly fraught with significant GI issues. Pfizer left us in the dark on details. ), it is also about smooth dosing and avoiding GI issues.
I still bet most humans rather wkly tiny shot vs one episode of vomit and continuous nausea
7.5 mg is the right dose as per my modeling likely equivalent to 12.5 mg tirzapetide in potency. This could be perfect to maintain wt long term.
q 2 wk dosing is pretty convenient and I would bet most humans will prefer it over pills ( although 27.5 mg pill that VK is testing in maintenance / same study may work as well )
We need an update on wed
